The Baltimore Pediatric ACTG, a collaborative effort between Johns Hopkins and the University of Maryland, was funded in 1988 with the intent of providing access to clinical trials for HIV-infected children throughout the city of Baltimore and the state of Maryland. Since its inception, the PBACTG has enrolled 244 children in 25 protocols with minimal loss to follow-up and has contributed substantially to the ACTG agenda, providing the chairs for major scientific committees, protocol chairs, and protocol team members. Both institutions remain highly committed to continuing and expanding these collaborative efforts. We propose to continue these activities with an emphasis on each of the four scientific areas prioritized by the PACTG CORC: perinatal transmission, primary therapy, opportunistic infections and immunology, Thus, the BPACTG will continue to participate in perinatal trials, phase I, II and III trials, and in trials evaluating immune-based therapy. Given our institutional resources, we believe these areas represent strengths within the BPACTG and are areas in which we will contribute substantially to the ACTG scientific leadership. Recent problems with enrollment and data management have been identified and are being addressed by the BPACTG leadership. We therefore anticipate enrolling well over the minimum number of protocol naive HIV-infected children and HIV-infected pregnant women required by the RFA. We expect to continue our high enrollment ang retention of minority groups, reflecting the demographics of HIV infection in the region, and through increased outreach efforts and collaboration with the JHU and UMAB Adolescent Clinics we expect to increase our enrollment of HIV-infected adolescents. During the past 8 years we have established an effective network of researchers and providers in the BPACTG who serve the HIV-infected youth and expectant women of the region. The addition of new investigators to the BPACTG has further strengthened each or our individual units and through our collaborative efforts we currently have the capability, organization, and linkages with the community to successfully provide HIV-infected infants, children, adolescents and pregnant women of the region with access to ACTG clinical trials.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01AI027565-12
Application #
2882153
Study Section
Special Emphasis Panel (ZAI1-OTP-A (01))
Program Officer
Batzold, Frederick
Project Start
1988-09-30
Project End
2001-02-28
Budget Start
1999-03-01
Budget End
2000-02-29
Support Year
12
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Johns Hopkins University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
045911138
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Lambert, John S; Moye Jr, Jack; Plaeger, Susan F et al. (2005) Association of selected phenotypic markers of lymphocyte activation and differentiation with perinatal human immunodeficiency virus transmission and infant infection. Clin Diagn Lab Immunol 12:622-31
Watts, D Heather; Lambert, John; Stiehm, E Richard et al. (2003) Progression of HIV disease among women following delivery. J Acquir Immune Defic Syndr 33:585-93
Lambert, John S; Harris, D Robert; Stiehm, E Richard et al. (2003) Performance characteristics of HIV-1 culture and HIV-1 DNA and RNA amplification assays for early diagnosis of perinatal HIV-1 infection. J Acquir Immune Defic Syndr 34:512-9
Lambert, J S; Watts, D H; Mofenson, L et al. (2000) Risk factors for preterm birth, low birth weight, and intrauterine growth retardation in infants born to HIV-infected pregnant women receiving zidovudine. Pediatric AIDS Clinical Trials Group 185 Team. AIDS 14:1389-99
Henderson, R A; Talusan, K; Hutton, N et al. (1999) Whole body protein turnover in children with human immunodeficiency virus (HIV) infection. Nutrition 15:189-94
Stiehm, E R; Lambert, J S; Mofenson, L M et al. (1999) Efficacy of zidovudine and human immunodeficiency virus (HIV) hyperimmune immunoglobulin for reducing perinatal HIV transmission from HIV-infected women with advanced disease: results of Pediatric AIDS Clinical Trials Group protocol 185. J Infect Dis 179:567-75
Henderson, R A; Talusan, K; Hutton, N et al. (1998) Resting energy expenditure and body composition in children with HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol 19:150-7
Lambert, J S; Viscidi, R; Walker, M C et al. (1997) Antibody to human immunodeficiency virus type 1 (HIV-1) gp160 in mucosal specimens of asymptomatic HIV-1-infected volunteers parenterally immunized with an experimental recombinant HIV-1 IIIB gp160 vaccine. The National Institute of Allergy and Infectious Clin Diagn Lab Immunol 4:302-8
Lambert, J S; Mofenson, L M; Fletcher, C V et al. (1997) Safety and pharmacokinetics of hyperimmune anti-human immunodeficiency virus (HIV) immunoglobulin administered to HIV-infected pregnant women and their newborns. Pediatric AIDS Clinical Trials Group Protocol 185 Pharmacokinetic Study Group. J Infect Dis 175:283-91
Henderson, R A; Talusan, K; Hutton, N et al. (1997) Serum and plasma markers of nutritional status in children infected with the human immunodeficiency virus. J Am Diet Assoc 97:1377-81

Showing the most recent 10 out of 20 publications